We have assessed ®ve signal transduction pathways to determine the role each might play in the malignant transformation of mammary epithelium initiated by neu, heregulin/NDF, TGFa, v-Ha-ras and c-myc in transgenic mice. The study involves a molecular and pharmacologic assessment of Erk/MAP kinase, Jnk/SAP kinase, PI 3-kinase, protein kinase C, and the Src-related kinases Lck and Fyn. Our results indicate that oncogenes capable of transforming mammary gland epithelium activate and require speci®c signal transduction pathways. For example, mammary tumors initiated by neu, vHa-ras and c-myc have high levels of active Erk/MAP kinase and their anchorage independent growth is strongly inhibited by PD098059, an inhibitor of Mek/ MAP kinase kinase. By contrast, Erk/MAP kinase activity is weak in tumors initiated by TFGa and heregulin/NDF and the corresponding cell lines are not growth inhibited by PD098059. Similarly, PI 3-kinase is strongly activated in neu, TGFa and heregulin/NDF initiated tumor cell lines, but not in c-myc or v-Ha-ras initiated tumor cell lines. The anchorage independent growth of all these tumor cell lines are, however, inhibited by the speci®c PI 3-kinase inhibitor LY294001. Further illustrating this oncogene-based speci®city, PP1, a speci®c inhibitor of the Src-like kinases, Lck and Fyn, blocks anchorage-independent cell growth only in the TGFa initiated mammary tumor cell line. Taken together with additional observations, we conclude that certain oncogenes reliably require the recruitment/activation of speci®c signal transduction pathways. Such speci®c relationships between the initiating oncogene and a required pathway may re¯ect a direct activating eect or the parallel activation of a pathway that is a necessary oncogenic collaborator for transformation in the mammary gland. The work points to a molecular basis for targeting therapy when an initiating oncogene can be implicated; for example, because of ampli®cation, increased expression, genetic alteration, or heritable characteristics.
Introduction
The occurrence of human breast cancer is associated with the ampli®cation and/or overexpression of a number of genes. Among these are genes that encode growth factors, growth factor receptors and transcription factors (Chrysogelos and Dickson, 1994; Dubik et al., 1996) . The signal transduction pathways that are involved in transformation by dierent oncogenes in the mammary gland are just beginning to be de®ned. A role for the mitogen activated protein kinases (MAPKs or Erks) in transformation by the ErbB2 receptor has been established by showing that overexpression of ErbB2 is associated with a considerably increased Erk/ MAP kinase activity in breast cancer cell lines (Janes et al., 1994) . Furthermore, the autophosphorylation sites in the ErbB2/Neu receptor that allow coupling to Ras and the Erk/MAP kinase pathway appear to be very important for cell transformation (Ben-Levy et al., 1994; Dankort et al., 1997) . The role of signal transduction pathways in transformation mediated by ligands of the EGF family is not well understood at present, but studies have shown that exogenously added EGF and heregulin/NDF can induce activation of the Erk/MAP kinases, Jnk/SAP kinases (stress activated protein kinases) and phosphatidyl inositol 3-kinase in mammary epithelial cell lines. In addition, overexpression of the ErbB2 receptor enhances and prolongs the stimulation of these two pathways in vitro (Karungaran et al., 1996; Marte et al., 1995; SeppLorenzino et al., 1996) . An antibody that blocks surface localization of ErbB2 has been shown to suppress heregulin/NDF and EGF mediated activation of Erk/MAP kinase and p70/p85 ribosome S6 kinase in T47D breast cancer cells indicating that the ErbB2 receptor is involved in mediating signals from the ligands of this family. This occurs despite the fact that these ligands do not bind ErbB2, but rather the EGF, ErbB3 and ErbB4 receptors. The same antibody inhibits heregulin/NDF induced stimulation of anchorage independent growth indicating a requirement for ErbB2 in heregulin/NDF mediated transformation and a possible involvement of the Erk/MAPK pathway and/or the p70/p85 ribosome S6 kinase .
Involvement of other signaling pathways and molecules in transformation of mammary epithelia is suggested by ®ndings showing elevated activity in breast carcinomas relative to normal breast tissues. The nonreceptor tyrosine kinase c-Src and protein kinase C (PKC) are good examples of signaling molecules that have been implicated in cancer of the breast by this means (Ottenho-Kal et al., 1992; Jacobs and Rubsamen, 1983; Rosen et al., 1986; Hennipman et al., 1989; Davidson and Kennedy, 1996) . In addition, mammary hyperplasia and tumors are seen in MMTV-c-src transgenic mice (Webster et al., 1995) . An inverse relationship has also been found between PKC activity and estrogen receptor (ER) status indicating that increased PKC activity might be associated with a more aggressive tumor type Borner et al., 1987) . Recently it has also been shown that Erk/MAP kinase activity is high in cancerous breast tissue compared to normal breast (Sivaraman et al., 1997) .
Our aim was to analyse the activation of and requirement for signal transduction pathways in mammary gland tumors initiated by dierent oncogenes. To do this, we used mammary tumors that arose in transgenic mice overexpressing the following oncogenes: neu, TGFa, heregulin/NDF, v-Ha-ras and c-myc. We realize that two sorts of pathways can be uncovered in such studies. One, of course, will be those that are themselves activated by a speci®c oncogene product. Of equal interest, will be those signal transduction pathways that are not directly activated by the initiating oncogene product, but which must nevertheless be activated in collaboration with the initiating pathway to bring about transformation.
We found that many signal transduction pathways are activated in an oncogene speci®c manner in both primary mammary tumors and their derived cell lines. In addition, inhibiting the activity of individual signaling pathways has very dierent eects on the transformed phenotype of these cells. In fact, there is in most cases a clear correlation between the activation and requirement for speci®c signaling pathways and the speci®c transgenic oncogene that initiated tumor formation. We have therefore established that there is a high degree of speci®city in the mechanisms by which oncogenes mediate transformation signals in mammary gland epithelia. It appears that even members of the same family of genes, such as the epidermal growth factor family of receptors and ligands, require dierent sets of signaling pathways for transformation.
Results
In the course of studies directed towards an understanding of the molecular basis for mammary carcinoma, we have created a variety of transgenic mice in which adenocarcinoma of the mammary gland results from the activation of one of several speci®c oncogenes. These transgenes are generally expressed in the mammary epithelium as a result of their fusion with the mouse mammary virus tumor virus (MMTV) promoter/enhancer (Stewart et al., 1984; Leder et al., 1986; Muller et al., 1988; Krane and Leder, 1996) . Such lines generate mammary gland tumors, the oncogenic behavior and morphology of which are directly dependent upon the speci®c oncogenic (initiating) transgene carried by the line (Cardi et al., 1991) . The availability of primary mammary tumors and tumor cell lines from these mice make it possible to relate the activity of speci®c signal transduction pathways to the initial oncogenic event provided by the particular transgene. Accordingly, we have used primary tumors and cell lines from three transgenic mouse lines expressing ligands and receptors of the EGF/ErbB family (Neu, TGFa and heregulin/ NDF) and from two other lines bearing v-Ha-Ras and c-Myc. All lines develop adenocarcinoma of the breast and thus provide an opportunity to assess various signal transduction pathways in transformed mammary epithelium.
Erk/MAP kinase activity in transgenic mouse mammary tumors correlates with the transforming oncogene
The extracellular regulated protein kinases (Erks) are serine/threonine kinases of the MAP kinase family. They are activated by growth factors, cytokines and hormones and mediate signals of mitogenesis, dierentiation and oncogenesis (Crews et al., 1992; Cowley et al., 1994; Mansour et al., 1994) . Therefore, the activity of the Erk/ MAP kinase signal transduction pathway was measured in cell lines derived from the mouse mammary gland tumors noted above. The activity of Erk1 and Erk2 kinases was measured in exponentially growing cultures under anchorage dependent conditions by assaying for phosphorylation of exogenous myelin basic protein (MBP) in Erk immunoprecipitates. Erk1 and Erk2 activity was found consistently to be higher in cell lines derived fron neu, v-Ha-ras and c-myc initiated tumors than in cell lines from heregulin/NDF or TGFa initiated tumors (shown for Erk1 in Figure 1a ). When Erk activity was normalized to protein levels in the immunoprecipitates, we repeatedly saw up to 15-fold higher kinase activities in neu, v-Ha-ras and c-myc initiated cell lines than in other tumor lines.
To verify that the dierence in Erk kinase activity we saw in the mammary tumor cell lines was not the result of events that occurred during in vitro growth, we measured activity in primary mammary gland tumors from MMTV-neu, MT-TGFa, MMTV-heregulin/NDF, MMTV-v-Ha-ras and MMTV-c-myc transgenic animals. An antibody that is speci®c for phosphorylated Erk/MAP kinase (a-phosphoErk(Tyr 204 )) was used to measure Erk1 phosphorylation in tumor lysates. As shown in Figure 1b , we saw the highest Erk1 phosphorylation in neu and v-Ha-ras initiated tumors, variable levels in c-myc tumors and low to undetectable levels in heregulin/NDF and TGFa initiated tumors. Since Erk phosphorylation on tyrosine 204 is an indicator of Erk activity, we conclude that cell lines derived from primary mammary gland tumors appear to be representative of the original tumors and that they can be used to study signaling pathways in an in vitro setting. Our ®ndings further imply that transformation of mouse mammary epithelial cells by neu and v-Ha-ras (and c-myc in some cases) is correlated with, or speci®cally induces high activation of the Erk/MAP kinase signal transduction pathway. This prompted us to investigate if mammary epithelial cells transformed by these three oncogenes required activation of the Erk pathway to maintain the transformed phenotype.
The Erk/MAP kinase pathway is needed for the anchorage independent growth of mammary epithelial cell lines transformed with the oncogenes neu, v-Ha-ras and c-myc
To establish the requirement of the Erk pathway for in vitro transformed growth, we measured anchorage independent growth of the mammary tumor cell lines in the presence and absence of a speci®c inhibitor for Mek, the kinase that phosphorylates and activates Erk1 and Erk2. This compound, PD098059, reversibly inhibits Mek activity towards Erk1 and Erk2 with an IC 50 value of about 10 mM without aecting any other known kinases (Dudley et al., 1995) . We ®rst veri®ed that PD098059 could indeed inhibit serum and phorbol 12-myristate 13-acetate (PMA) induced Erk/MAP kinase activation in NIH3T3 ®broblasts at 10 and 30 mM concentration. In addition, PD098059 inhibited Erk/MAP kinase activity in the mammary tumor cell lines without aecting Jnk/SAP kinase, PI 3-kinase, Fyn or Lck (data not shown).
When the mammary cell lines were examined for their growth in soft agar with and without 10 mM PD098059, we found that lines derived from neu, v-Haras and c-myc initiated tumors were strongly inhibited (about 35 ± 80% depending on the line), whereas cell lines from TGFa and heregulin/NDF initiated tumor lines were not (Figure 2a) . Repression of transformed growth therefore correlated with cell lines in which high Erk/MAP kinase activities were seen. At a higher concentration, 30 mM PD098059, anchorage independent growth of neu, v-Ha-ras and c-myc initiated tumor cells was inhibited about 90 ± 100%, but TGFa and heregulin/NDF initiated cell lines were still not aected (Figure 2b) . Curiously, a cell line initiated by heregulin/ NDF was stimulated to grow under anchorage independent conditions, especially in the presence of 10 mM of inhibitor. Our results indicate that neu, v-Haras and c-myc transformed mammary cell lines have high levels of active Erk/MAP kinase pathway under normal growth conditions and, in addition, are very sensitive to the inhibition of this pathway for transformation. This might indicate that the oncogenes v-Ha-ras, neu and c-myc strongly require the Erk/MAP kinase pathway in order to transform mammary epithelial cells or to sustain the transformed phenotype. On the other hand, transformation by
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Figure 1 Erk/MAP kinase activity is high in cell lines derived from neu, v-Ha-ras and c-myc initiated mammary tumors compared to TGFa and heregulin/NDF initiated tumors. Erk activity was measured in mammary tumors and cell lines transformed with c-myc, TGFa, heregulin/NDF, neu and v-Haras. (a) shows Erk kinase activity in tumor derived cell lines. Protein lysates were made from exponentially growing cultures followed by immunoprecipitation with aErk1 antibodies. One half of each immunoprecipitate was used for a kinase assay using exogenous myelin basic protein (MBP) as a substrate. Samples were resolved on SDS ± PAGE gels and bands visualized by autoradiography. The other half of the immunoprecipitate was used for Western analysis with the same Erk speci®c antibodies to normalize for protein levels in the immunoprecipitates. The top panel shows Erk1 kinase activity and the bottom panel Erk1 protein levels in the mammary tumor cell lines. Erk2 activities showed similar levels as Erk1 (not shown). Negative and positive controls are NIH3T3 ®broblasts starved, and treated with 100 ng/ ml phorbol 12-myristate 13-acetate (PMA) for 5 min respectively. Experiments were repeated at least three times each and representative ®gures are shown. In (b), Erk1 phosphorylation was measured as an indicator of Erk1 activity in primary mammary gland tumors. Lysates were made from tumors that arose in transgenic mice overexpressing c-myc, TGFa, heregulin/ NDF, neu and v-Ha-ras in the mammary gland. Equivalent amounts of proteins from tumor lysates were resolved on SDS ± PAGE gels, transferred to PVD membranes and subjected to Western blot analysis with a phospho-speci®c Erk antibody (recognizes Erk proteins when phosphorylated on Tyr TGFa or heregulin/NDF does not appear to be dependent on the Erk/MAP kinase pathway.
The role of phosphatidyl inositol 3-kinase in transformation of mammary epithelial cell lines Our ®nding that oncogenes might utilize dierent signaling pathways to transform the mammary gland prompted us to investigate the activity of other well known signaling molecules and pathways in our cell lines and tumors. Phosphatidyl inositol 3-kinase (PI 3-kinase) is a well known enzyme that is often phosphorylated and activated in response to growth factor receptors binding their respective ligands (Solto et al., 1992; Carpenter and Cantley, 1990) . As shown in Figure 3 , we measured tyrosine phosphorylation of the p85 regulatory subunit of PI 3-kinase as an indicator of PI 3-kinase activation in the mouse mammary tumor cell lines. Robust phosphorylation was detected in cultures from TGFa, heregulin/NDF and neu initiated tumors, but cells from c-myc and v-Ha-ras induced tumors had low to undetectable levels. A lipid kinase assay on aphosphotyrosine immunoprecipitates using exogenous phosphatidyl inositol as a substrate (data not shown) con®rming our ®ndings, indicating that TGFa, heregulin/NDF and Neu might speci®cally induce high levels of activation of PI 3-kinase in cells growing under normal conditions in vitro.
A selective PI 3-kinase inhibitor, LY294002, was used to assess the requirement of PI 3-kinase for anchorage independent growth of the mammary tumor cell lines (Figure 4 ). This compound reversibly inhibits PI 3-kinase by competing with ATP for its binding site with an IC 50 of about 1.4 mM. No other kinases have been found to be inhibited by LY294002 at the concentrations used here Sanchez-Margalet et al., 1994) . We veri®ed that PI 3-kinase activity was inhibited in the mammary cell lines when they were treated with LY294002 (by measuring tyrosine phosphorylation of the p85 subunit) and that Erk/MAP kinase, Jnk/SAP kinase, Fyn and Lck were not aected (data not shown). As shown in Figure 4 , LY294002 signi®cantly inhibited anchorage independent growth of TGFa, neu and c-myc initiated cell lines at 3 mM, but did not alter growth of heregulin/NDF and v-Ha-ras initiated cell lines. At 10 mM of LY294002 growth of all tumor cell lines was signi®cantly aected. It therefore appears that tumor cell lines initiated with all the oncogenes tested here require PI 3-kinase for their transformed behavior even though PI 3-kinase activity was hardly detectable in cmyc and v-Ha-ras initiated cell lines under normal anchorage dependent growth conditions. Activation of the c-Jun kinase (Jnk/SAPK) pathway is seen in some heregulin/NDF, c-myc and v-Ha-ras initiated mammary tumors
The c-Jun N-terminal kinase (Jnk or stress activated protein kinase, SAPK) pathway is induced in response to environmental stress such as U.V. light, g radiation, protein synthesis inhibitors and DNA damaging agents (Hibi et al., 1993; Kyriakis et al., 1994; Derijard et al., 1994) . Furthermore, it is also activated in response to mitogenic signals such as growth factors and activated Ras (Minden et al., 1994; Derijard et al., 1994) . We measured Jnk activity in mammary tumor cell lines by a kinase assay with c-Jun as a substrate in Jnk immunoprecipitates, and in mammary tumors from transgenic animals by using an antibody speci®c for Jnk/SAPK-phosphorylated c-Jun (a-phospho-cJun(Ser 63 )II) on Western blots. We repeatedly saw high activity of Jnk in a heregulin/NDF initiated tumor cell line and not in c-myc, v-Ha-ras, neu or TGFa initiated tumor cell lines (Figure 5a ). However, primary tumors initiated by c-myc and v-Ha-ras had variable levels of c-Jun phosphorylation but heregulin/NDF, TGFa, and neu induced tumors were all negative ( Figure 5b) . A speci®c phospho-Jnk antibody con®rmed these ®ndings (not shown). This suggests that the Jnk/SAP kinase pathway is not activated in an oncogene speci®c manner in mammary tumors. Lack of speci®c Jnk/SAP kinase inhibitors do not allow us Figure 3 Phosphatidyl inositol 3-kinase activity is high in TGFa, heregulin/NDF and neu initiated tumor cell lines compared to cell lines initiated with c-myc and v-Ha-ras. Lysates were made from exponentially growing cultures of mammary tumor cells. Equivalent protein amounts were immunoprecipitated with an antiphosphotyrosine antibody (4G10) and then resolved on SDS ± PAGE gels. Western analysis was then performed with an anti-PI 3-kinase antibody (ap85). A431 cells treated with 100 nM EGF for 5 min were used as a positive control. A lipid kinase assay using exogenous phosphatidyl inositol (PI) as a substrate con®rmed the data Figure 4 A speci®c phosphatidyl inositol 3-kinase inhibitor aects anchorage independent growth of all cell lines. Soft agar assays were performed as described in Figure 2 . LY294002, a speci®c PI 3-kinase inhibitor was used at 3 ± 10 mM concentrations. Dishes were treated with either media alone (DMEM/ 10%BCS) or media plus inhibitor and stained with nitrobluetetrazolium (NBT) and counted after 2 ± 3 weeks. Vehicle (1 : 1000 DMSO) was added to control dishes. LY: LY294002. The experiment was repeated at least two times and n=3+s.e.
to test the requirement for this pathway in transformed growth in vitro.
Protein kinase C (PKC) requirement for the transformed phenotype of tumor derived cell lines PKC is a family of closely related isoenzymes which have important roles in signal transduction regulating the growth and dierentiation of many cell types (Nishizuka, 1986 (Nishizuka, , 1988 . We have used three inhibitors to assess the importance of PKC in in vitro transformation of mammary epithelial cells. These are two staurosporine analogues: bisindolylmaleimide (GF109203X) and UCN-01 (7-hydroxystaurosporine), and H7. Bisindolylmaleimide is a selective inhibitor for PKC at the concentrations used here (isoforms a, b1, b2 and g), but H7 and UCN-01 also inhibit other kinases such as PKA (Toullec et al., 1991; Tamaoki et al., 1990) . Results from anchorage independent growth assays with these inhibitors are shown in Figure 6 . UCN-01 and H7 were extremely potent, inhibiting anchorage independent growth of c-myc, TGFa, neu and v-Ha-ras initiated mammary tumor cells almost completely and also strongly aecting the heregulin/NDF initiated tumor cell line. The only PKC speci®c inhibitor, bisindoylmaleimide, was in general much less eective with the strongest inhibition on anchorage independent growth of v-Ha-ras initiated cell lines. The three PKC inhibitors used here were also tested against Erk/MAP kinase, Jnk/SAP kinase, Fyn and Lck and did not inhibit any of these kinases (not shown).
The Src-related kinases Fyn and Lck are required for TGFa-mediated transformation
The nonreceptor tyrosine kinase Src and its related kinases, Yes, Fyn and Lck have been implicated in various cell functions such as cell to cell contact, dierentiation and proliferation (Taylor and Shalloway, 1996) . The activities of Src, Fyn and Lck were measured in the mammary cell lines by in vitro kinase assays using exogenous enolase as a substrate and were not oncogene speci®c (data not shown). We then used a synthetic inhibitor that is speci®c for Fyn and Lck to test the importance of Src-related proteins in in vitro transformation of mammary tumor cell lines. The inhibitor, PP1, inhibits Fyn and Lck at concentrations that are signi®cantly lower than those required to inhibit other known kinases (IC 50 values for Fyn and Lck are 6 and 5 nM, respectively) (Hanke et al., 1996) . Although PP1 also inhibits Src, Hck and the EGFR, the concentrations that are required are higher and therefore not selective. We veri®ed that PP1 indeed inhibits Fyn and Lck in our mammary cell lines and does not aect PI 3-kinase, Erk/MAP kinase or Jnk/ SAP kinase at the concentration used here (data not shown). As shown in Figure 7 , we found that 50 nM PP1 potently inhibited anchorage independent growth of a TGFa initiated tumor cell line (about 50% inhibition), whereas it did not notably modify Figure 6 Protein kinase C inhibitors have variable eects on anchorage independent growth. Soft agar assays were performed as described in Figure 2 . Three PKC inhibitors were used: H7 at 40 mM (inhibits both PKC and PKA), UCN-01 at 50 nM (inhibits both PKC and PKA) and bisindoylmaleimide at 1 mM (a speci®c inhibitor for PKC isoforms a, b1, b2 and g at the concentrations used here). Dishes were treated with either media alone (DMEM/ 10%BCS) or media plus inhibitors and stained with nitrobluetetrazolium (NBT) and counted after 2 ± 3 weeks. Vehicle (1 : 1000 DMSO) was added to control dishes. The experiment was repeated at least two times and n=3+s.e. Note the much stronger eects of the inhibitors H7 and UCN-01 which inhibit both PKC and PKA anchorage independent growth of c-myc, heregulin/ NDF and neu derived cell lines. Surprisingly, v-Ha-ras initiated mammary cell lines were induced to grow in soft agar by 50 nM PP1. Our results imply that the Srcrelated kinases Fyn and Lck might be required for TGFa mediated transformation, but could suppress ras mediated transformation of mammary epithelial cells. We also tested the eects of PP1 on the anchorage independent growth of two v-Ha-ras initiated fibrosarcoma cell lines (derived from the same transgenic mouse line as the mammary cell lines) and found no eects indicating a possible mammary speci®c phenomena of induced growth when Fyn and Lck activity is repressed (not shown).
Discussion
We have shown here that two signal transduction pathways are activated in an oncogene speci®c manner in mammary tumors and their derived cell lines growing under normal anchorage dependent conditions. The Erk/MAP kinase pathway is strongly active in neu and v-Ha-ras initiated mammary tumors as compared to TGFa and heregulin/NDF initiated tumors, and PI 3-kinase activity was seen only in TGFa, heregulin/NDF and neu initiated tumor cell lines. This speci®city suggested that oncogenes might use dierent signaling pathways in order to transform mammary epithelial cells. We tested that hypothesis by looking at the eects of synthetic inhibitors of various pathways under anchorage independent conditions in vitro.
A speci®c inhibitor of the Erk/MAP kinase pathway inhibited anchorage-independent growth only in cell lines initiated by neu, v-Ha-ras, and c-myc. These were the cells that showed high kinase activity, suggesting that these initiating oncogenes lead to Erk activation and require it for transformation. Although this signaling pathway has been strongly implicated in growth and transformation in many cell systems (Crews et al., 1992; Cowley et al., 1994; Mansour et al., 1994) , our study indicates that it is not absolutely required for the transformed phenotype of mammary cells per se but rather for cells transformed by speci®c oncogenes (i.e. neu, v-Ha-ras and in some cases c-myc, but not TGFa or heregulin/NDF). Taken together with recent studies showing that Erk/MAP kinase is overexpressed and its activity is signi®cantly higher in cancerous as compared to normal breast tissues, our results suggest that targeting of the Erk/MAP kinase pathway could be an eective way to treat this malignancy (Sivaraman et al., 1997) . In addition, our studies suggest that it is important to know which genes are ampli®ed or overexpressed in a particular breast malignancy, in order to choose which signal transduction pathways to attack in therapy. Our work also agrees with the concept that tumors initiated with dierent oncogenes express dierent molecular markers. Dierential expression of such genes would be expected to in¯uence tumor progression and malignancy (Morrison and Leder, 1994; Elson and Leder, 1995; Kitsberg and Leder, 1996) .
The role of the PI 3-kinase pathway is of particular interest. Three classes of mammary tumor cell lines, initiated by TGFa, neu, and heregulin/NDF, showed high levels of active PI 3-kinase compared to v-Ha-ras and c-myc induced mammary tumor cell lines. Our results showing that a TGFa initiated cell line is especially sensitive to low concentrations of LY294002 are also noteworthy in light of studies with neutralizing antibodies demonstrating that PI 3-kinase is required for signaling by the EGF receptor (Auger et al., 1989; Jackson et al., 1992; Roche et al., 1994) . Furthermore, studies with a dominant negative p85 construct (encoding a mutant version of the regulatory subunit of PI 3-kinase) and chemical inhibitors such as we use here, have showed that PI 3-kinase is required for EGF receptor mediated transformation of mouse epidermal cells in vitro (Huang et al., 1996) .
The Src-related kinases Lck and Fyn seemed to be required for the anchorage independent growth of a TGFa initiated tumor cell line only. Overexpression of Src has been reported to potentiate EGF-mediated mitogenic response in murine ®broblasts in vitro, whereas a dominant negative Src inhibits EGFinduced mitogenic stimulation (Luttrell et al., 1988; Wilson et al., 1989) . In addition, Src and the EGF receptor synergize in inducing DNA synthesis, anchorage independent growth as well as tumor formation in vivo (Maa et al., 1995) . Such results and those we report here indicate that Src and possibly Srcrelated kinases might be very important for transformation mediated by the TGFa/EGFR system in breast cancer as well as other malignancies. Many human breast tumors show elevated Src activity (OttenhoKal et al., 1992) , but it is not known whether the same tumors frequently have activated EGF receptormediated signaling pathways.
An unexpected consequence of interfering with the Fyn and Lck pathways was observed in v-Ha-ras initiated cell lines. Surprisingly, anchorage independent growth of these cell lines was induced dramatically in the presence of selective concentrations of an inhibitor for Fyn and Lck. These results indicate that one or both of these nonreceptor tyrosine kinases might negatively regulate transformation of mammary Figure 7 The Src related kinases Fyn and Lck are required only for anchorage independent growth of TGFa initiated mammary tumor cells, but induce v-Ha-ras initiated cells. Soft agar assays were performed on mammary tumor cell lines as described in Figure 2 . PP1, a speci®c inhibitor for Fyn and Lck was used at a 50 nM concentration. Dishes were treated with either media alone (DMEM/10%BCS) or media plus inhibitor and counted after 2 ± 3 weeks. Vehicle (1 : 1000 DMSO) was added to control dishes. The experiment was repeated at least two times and n=3+s.e. epithelial cells by Ras. A possible explanation for our results stems from studies showing that Lck and Src phosphorylate Ras-GTPase activating protein (Ras-GAP) (Ellis et al., 1990 (Ellis et al., , 1991 Park et al., 1992; Amrein et al., 1992) . If this phosphorylation is associated with increased activity of Ras-GAP, one would expect to increase the GTPase activity towards Ras and therefore induce a downregulation of Rasmediated signal transduction (van der Geer et al., 1997; Schezek et al., 1997) . Alternatively, Fyn and Lck could activate phosphatases or other proteins that negatively regulate one or more downstream eectors of Ras. Taken to its logical extreme, such results would mitigate against the use of Src-kinase inhibitors in the treatment of ras initiated tumors.
The heregulin/NDF initiated cell line was the most resistant to the inhibitors used in this study. This might indicate that heregulin/NDF induces transformation of mammary epithelial cells via signaling pathways that are either unidenti®ed or not included in this study. Heregulin/NDF has been shown to induce proliferation or dierentiation of mammary epithelial cells in vitro and in both cases activate Erk kinases and p70/p85 S6 kinase (Marte et al., 1995) . In our study, activation of Erk kinase was low to absent in heregulin/NDF initiated tumors and tumor-derived cells, and inhibition of this pathway did not decrease anchorage independent growth in a heregulin/NDF initiated tumor cell line. Strong activation of Jnk/SAP kinase was seen in a heregulin/NDF initiated cell line but was not reproduced in primary mammary tumors from MMTV-heregulin/NDF transgenic mice.
Although Erk/MAP and Jnk/SAP kinase activation was consistent in c-myc initated tumor cell lines, primary mammary tumors derived from c-myc overexpressing transgenic mice showed variable levels of activity of both these pathways. C-myc derived tumor cells were very sensitive to inhibition of the Erk/MAP kinase pathway and PI 3-kinase suggesting that in order to transform cells, the c-Myc protein needs cooperating signals that originate at the cell membrane, probably from growth factors and their receptors. Cmyc has been shown to be a potent oncogene when its apoptotic properties are repressed and this could be achieved by upregulation of various growth factormediated signal transduction pathways. Indeed, multiple growth factors and PI 3-kinase can suppress myc induced apoptosis (Harrington et al., 1994; Dolnikov et al., 1996; Amundadottir et al., 1996; Kaumann-Zeh et al., 1997) . Additionally, c-Myc might be downstream of Fyn and Lck on the same signaling pathway (as has been shown for Src) explaining why the Fyn/Lck inhibitor PP1 does not eectively aect transformed growth of c-myc initiated mammary tumor cell lines (Barone and Courtneidge, 1995) .
Our study has showed that the initiating oncogene determines in many cases what signal transduction pathways are activated and utilized to maintain the transformed phenotype in mammary gland epithelial cells in vitro. Activation of a single signaling pathway is probably not sucient for transformation in the mammary gland and a more likely scenario is that a combination of pathways are used to this end. Targeting many pathways could therefore be the best possible treatment of breast cancer and, in addition, our results suggest that knowledge of the initiating oncogene might assist in deciding which pathways to target. If we assume that the mammary tumor cell lines have not developed indirect mechanisms of drug resistance, then we might conclude that none of these pathways are absolutely required for mammary gland transformation since no inhibitor blocked anchorage independent growth in all of our mammary tumor cell lines. Although the synthetic inhibitors we used in this study have been tested against a variety of signaling proteins and found to be selective at the concentrations used here one cannot exclude the possibility that they could have an eect on yet undiscovered proteins. Therefore, more formal in vivo experiments are underway to establish the requirement for speci®c signaling pathways in mammary gland transformation using transgenic and knockout mouse strains.
Materials and methods

Cell lines and tumors
Mouse mammary cell lines are derived from mammary tumors arising in transgenic mice. Neu, heregulin/NDF, TGFa, v-Ha-ras and c-myc were expressed in the mammary gland from the mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter/enhancer, the mouse metallothionein promoter (MT) or the zeta globin promoter. The following cell lines were used: 16MB9A, M158, 13Mala and Myc#83 from mammary tumors arising in MMTV-c-myc transgenic mice (line M) (Stewart et al., 1984; Leder et al., 1986; Amundadottir et al., 1996) ; IJ9921 from a MMTV-heregulin/NDF transgenic mouse tumor (line TG.IJ) (Krane and , TGFa#13 from a MT-TGFa mouse (MT100 line) (Jhappan et al., 1990; Amundadottir et al., 1996) ; n-Neu from a MMTV-c-neu mouse (nonactivated Neu, line N202) (Guy et al., 1992) ; NF639, SMF and NAF from MMTV-neu mice (activated Neu; line TG.NF) (Muller et al., 1988) ; SH1.1 from a MMTV-v-Ha-ras mouse (TG.SH line) and AC236, AC711 and AC816 from zeta globin promoter-v-Ha-ras mice (TG.AC line) (Sinn et al., 1987; Leder et al., 1990) . The cells were routinely grown in DMEM supplemented with 10% bovine calf serum (Gibco-BRL, Gaithersburg, MD), 4 mM glutamine (Bio-Whittaker, Walkersville, MD), penicillin (50 U/ml) and streptomycin (50 mg/ml) (Sigma, St Louis, MO). Mammary tumors arose in the following transgenic mouse strains: MMTV-c-myc (line M), MMTVheregulin/NDF (line TG.IJ), MT-TGFa (line MT100), MMTV-TGFa, (Matsui et al., 1990) , MMTV-neu (line TG.NF) and MMTV-v-Ha-ras (line TG.SH). Tumors from the MT-TGFa line were a generous gift of Dr Glenn Merlino, of the NIH.
Kinase assays for Erk/MAP kinases
Assessment of Erk/MAP kinase activity was performed by an in vitro kinase assay on Erk immunoprecipitates. Mammary tumor cell lines were plated in 100 mm plates and fed normal growth media the next day. Subcon¯uent cultures were harvested 2 days later by rinsing with cold phosphate-buered saline (PBS) and cells were lysed in a NP40 buer (50 mM Tris pH 7.6, 150 mM NaCl, 1% NP-40) with the Complete TM protease inhibitor cocktail (Boehringer Mannheim, Indianapolis, IN) and 1.0 mM sodium orthovanadate. Protein concentration in the lysates was measured using the Bradford-reagent (BioRad, Richmond, CA) with bovine serum albumin as a standard. Equivalent protein amounts were used for each immunoprecipitation. One mg of a-Erk1 (C-16) or a-Erk2 (C-14) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the lysates, together with 40 ml of a 50% suspension of protein A-sepharose beads in PBS. After 4 ± 6 h incubation at 48C the beads were washed three times in lysis buer, once with ST buer (50 mM Tris pH 8.0, 150 mM NaCl) and once with kinase buer (25 mM Tris pH 7.6, 10 mM MgCl 2 , 0.1 mg/ml BSA and 15 mM cold ATP). At this point the immunoprecipitates were divided into two parts and one half was used for the kinase reaction and the other half was used for Western analysis to normalize for Erk protein levels in the lysates. The immune complex kinase assay was performed with 5 mg myelin basic protein (MBP, Sigma) and 10 mCi [g 32 P]ATP in kinase buer for 10 min at 308C and reactions were terminated by adding SDS loading buer. Samples were separated by SDS ± PAGE and visualized by autoradiography. Kinase assay gels were scanned on a phosphoroimager (Molecular Dynamics, Sunnyvale, CA).
In order to normalize kinase activities for Erk protein levels, one half of each immunoprecipitate was separated on 10% SDS ± PAGE and transferred to Immobilon-P membranes (Millipore Corporation, Bedford, MA). Blots were blocked with 5% milk in TBST (10 mM Tris, pH 7.4, 150 mM NaCl, 0.2% Tween-20) for 1 h at room temperature and then incubated overnight in TBST with 5% BSA and the appropriate antibody. Antibodies used for kinase assay normalization were: a-Erk1 (C-16) and a-Erk2 (C-14) at 1 : 1000 dilution (Santa Cruz Biotechnology). Proteins were visualized with an HRP-linked second antibody and a chemiluminescent detection system (ECL, Amersham, Buckinghamshire, England). Bands were scanned on a densitometer (Molecular Dynamics, Sunnyvale, CA) and kinase activity levels normalized to Erk protein levels.
Kinase assays for Jnk/SAP kinase
Cell lysates were prepared from exponentially growing cultures, as described above for Erk/MAP kinase, with a Triton X-100 lysis buer (25 mM HEPES pH 7.5, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 500 mM NaCl, 50 mM NaI, 5 mM EDTA) with the Complete TM protease inhibitor cocktail (Boehringer Mannheim) and 1.0 mM sodium orthovanadate. Protein concentration in the lysates was measured using the Bradford-reagent (BioRad) with bovine serum albumin as a standard. Equivalent protein amounts were used for each immunoprecipitation. One mg of an a-Jnk (FL) antibody (Santa Cruz Biotechnology) and 40 ml of a 50% suspension of protein A-sepharose beads in PBS were added to the lysates. After 4 ± 6 h incubation at 48C the beads were washed three times with lysis buer and once with kinase buer: 25 mM HEPES pH 7.5, 20 mM MgCl 2 , 20 mM b-glycerophosphate, 2 mM DTT and 1.0 mM sodium orthovanadate. The kinase assay was performed with 1 mg of GST-c-Jun(1 ± 169) (Upstate Biotechnology Incorporated, Lake Placid, NY) and 10 mCi [g 32 P]ATP in kinase buer for 20 min at 308C (Hibi et al., 1993) . Reactions were terminated by adding SDS loading buer and the samples were separated by SDS ± PAGE and visualized by autoradiography. Kinase assay gels were scanned on a phosphoroimager (Molecular Dynamics, Sunnyvale, CA).
Western analysis
Exponentially growing cells or tumor tissues were lysed in an NP40 buer (50 mM Tris pH 7.6, 150 mM NaCl, 1% NP-40) with the Complete TM protease inhibitor cocktail (Boehringer Mannheim) and 1.0 mM sodium orthovanadate. Equivalent protein amounts (Brandford-reagent from Bio-Rad) were separated on 10% SDS ± PAGE and transferred to Immobilon-P membranes (Millipore Corporation). The following phospho-speci®c antibodies for Assays of phosphatidyl inositol 3-kinase (PI 3-kinase) activity Cell lysates were made from subcon¯uent cultures as described above. Lysis buer consisted of 137 mM NaCl, 20 mM Tris pH 7.6, 1 mM MgCl 2 , 1 mM CaCl 2 , 10% glycerol, 1% NP-40, 0.2 mM sodium orthovanadate and 1 mM phenylmethylsulfonyl¯uoride. Equivalent protein amounts were immunoprecipitated using 1.5 mg of an aphosphotyrosine antibody (aPTyr) (4G10, Upstate Biotechnology Incorporated, Lake Placid, NY). Samples were then separated on SDS ± PAGE gels and Western analysis performed with an antibody to the regulatory subunit of PI 3-kinase (ap85 antibody 06-195 from UBI). A horseradish peroxidase-linked secondary antibody and chemiluminescence (ECL, Amersham) were used to visualize phosphorylated proteins.
A lipid kinase assay was also performed on aPTyr immunoprecipitates (prepared as described above) to verify that phosphorylation of p85 was indicative of PI 3-kinase activity. This was done by incubating the immunoprecipitate at 228C for 10 min with g-[ 32 P]ATP and exogenous phophatidylinositol (Avanti Polar Lipids Inc, Alabaster, AL) as a substrate. Inositols were then extracted with a 1 : 1 mixture of chloroform/methanol and separated by thin layer chromatography (TLC) (VWR, Boston, MA) (Solto et al., 1994) . Phosphorylated PIs were visualized on a phosphoroimager.
Anchorage independent growth assays
Cells (10 4 ) were suspended in 0.36% bactoagar (Difco, Detroit, MI) and seeded into 35 mm dishes over a 0.6% agar base layer in DMEM plus 10% BCS. Every 4 days, about 300 ml of media with treatments was added to each plate. After 2 ± 3 weeks, colonies were stained overnight with 0.5 mg/ml nitrobluetetrazolium (NBT, Sigma) in PBS and counted. Each experiment was performed in triplicates and repeated at least two times. Treatments were: PD098059 10 ± 30 mM (generous gift of Dr David Dudley, Parke-Davis Pharmaceutical Research Division, WarnerLambert Co, Ann Arbor, MI), LY294002 3 ± 10 mM (Calbiochem, La Jolla, CA), H7 40 mM (Seikagaku America, Ijamsville, MD), bisindolylmaleimide 1 mM (GF109203X, Calbiochem), UCN-01 50 nM (generously provided by Dr Edward A Sausville at the Developmental Therapeutics Program, NCI, NIH, Bethesda, MD) and PP1 at 50 nM (Calbiochem). All treatments were given in normal growth media with 10% BCS. Vehicle (1 : 1000 DMSO) was added to control dishes. Lambert Co, Ann Arbor, MI for PD098059 and Michael D Johnson, Georgetown University, Washington DC for reagents. Finally, we thank members of the Leder lab and Ari Elson, the Weizmann Institute of Science, Israel for their critical reading of the manuscript and helpful discussions.
